Can Lexapro (escitalopram) cause increased intraocular pressure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Lexapro Cause Increased Eye Pressure?

Yes, Lexapro (escitalopram) can cause increased intraocular pressure and precipitate acute angle-closure glaucoma, though this is a rare adverse effect that occurs primarily in patients with anatomically narrow angles. 1

Mechanism of Action

Escitalopram can increase intraocular pressure through multiple pathways:

  • Uveal effusion mechanism: The most well-documented mechanism involves ciliochoroidal effusions with ciliary body detachments that cause forward rotation of the lens-iris diaphragm, leading to angle closure 1

  • Adrenergic effects: SSRIs including escitalopram have weak adrenergic properties that can cause mydriasis (pupil dilation), which bunches peripheral iris tissue into the drainage angle in susceptible patients 2, 3

  • Serotonergic pathway: Elevated serotonin levels from SSRI therapy may directly affect intraocular pressure regulation, though the exact mechanism remains incompletely understood 2

Clinical Evidence

A documented case report demonstrates the causal relationship:

  • A 41-year-old woman developed bilateral acute angle-closure glaucoma within days of starting escitalopram 1

  • High-frequency ultrasonography confirmed bilateral choroidal effusions with ciliary body detachments 1

  • Standard treatments (topical antihypertensives and laser peripheral iridotomy) failed to control the pressure 1

  • Discontinuation of escitalopram plus topical cycloplegics and corticosteroids resulted in complete resolution within 4 days, with normalization of intraocular pressures and resolution of uveal effusions 1

Risk Factors for SSRI-Induced Angle Closure

Patients at highest risk include those with:

  • Anatomically narrow anterior chamber angles (the primary risk factor) 4, 3

  • Hyperopia (farsightedness), especially older patients with natural lenses 4

  • Family history of glaucoma 5

  • Advanced age (angle becomes progressively narrower with aging) 3

Clinical Recommendations

Before starting Lexapro:

  • Ophthalmologic evaluation with gonioscopy should be performed in patients with known narrow angles or risk factors for angle closure 4

  • Consider prophylactic laser peripheral iridotomy if narrow angles are confirmed and escitalopram is deemed necessary 4

During treatment:

  • Monitor for acute angle-closure symptoms: sudden eye pain, redness, blurred vision, halos around lights, headache, and nausea 4, 1

  • Ophthalmological consultations should be considered during treatment with any SSRI in patients with glaucomatous risk factors, especially elderly patients 2

If angle closure occurs:

  • Immediately discontinue escitalopram 1

  • Initiate topical cycloplegics and corticosteroids 1

  • Standard glaucoma medications may be ineffective until the underlying uveal effusion resolves 1

  • Laser peripheral iridotomy is typically ineffective for drug-induced uveal effusion-type angle closure (unlike pupillary block mechanisms) 1

Important Caveats

The incidence of SSRI-related intraocular pressure modifications is likely underestimated because:

  • Most cases are asymptomatic or cause only vague visual disturbances that patients may not report 2

  • Progressive or intermittent angle closure may develop slowly without dramatic symptoms 2

  • Visual disturbances are often dismissed as unrelated to medication 2

This is NOT a contraindication to using Lexapro in patients with well-controlled open-angle glaucoma, as the mechanism differs entirely from the uveal effusion/angle closure mechanism described above 6, 7.

References

Guideline

Antihistamines and Topiramate-Induced Angle Closure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Effect of Ephedrine on Intraocular Pressure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Drug-induced ocular disorders.

Drug safety, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.